FORTREA HOLDINGS INC (FTRE) Stock News
NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD
FTRE Latest News, Press Relases and Analysis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such...
1 Cash-Producing Stock That Stand Out and 2 to Be Wary Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call
Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call
DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such...
1 Oversold Stock Primed to Rebound and 2 to Approach with Caution
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such...
Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm
Mentions: IBTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such...
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such...
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.
Why Fortrea (FTRE) Shares Are Plunging Today
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, operating profits, and earnings all falling short of Wall Street's expectations. Not exactly the kind of report investors like to see. But if there's a silver lining, it's the book-to-bill ratio of 1.35x which means demand for future orders is still strong, even though current revenues took a hit.
Fortrea (NASDAQ:FTRE) Misses Q4 Revenue Estimates, Stock Drops
Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.8% year on year to $697 million. The company’s full-year revenue guidance of $2.5 billion at the midpoint came in 8.7% below analysts’ estimates. Its non-GAAP profit of $0.18 per share was 50.7% below analysts’ consensus estimates.